BiOptic Awarded U.S. Patent for “Glycan Profiling Utilizing Capillary Electrophoresis”
2025-11-24
In the field of glycoscience and glycobiology, Academician Chi-Huey Wong has long been one of Taiwan's most influential scientific leaders. His groundbreaking research in glycan chemistry, biomedical applications, and vaccine strategies has not only elevated Taiwan's presence on the global stage, but has also earned him recognition from major international media as a strong contender for the Nobel Prize in Chemistry.
From 17 to 20 November 2025, MEDICA will once again gather international experts from the medical industry in Düsseldorf, Germany.
With over 5,000 exhibitors from 72 countries and 80,000 visitors MEDICA in Düsseldorf is one of the largest medical B2B trade fairs in the world. It offers a central stage for innovative products and services from the fields of medical imaging, laboratory technology, diagnostics, health IT, mobile health as well as physiotherapy/orthopaedic technology and medical consumables.
The AMP 2025 Annual Meeting & Expo is the only educational event developed and presented by internationally renowned molecular diagnostic professionals. As the premier event for molecular diagnostics, AMP historically hosts 2,200+ molecular medicine professionals from around the globe, representing every aspect of the molecular diagnostics industry.
Life Sciences Baltics is the leading event in the Baltic region, connecting global life sciences professionals. This event provides unique opportunities for project initiation, lead generation, and strategic partnerships through an extensive exhibitor showcase, insightful conferences, a dedicated partnering area, diverse networking formats, and competitions, including a startup pitch challenge.
BiOptic Inc. Reports NT$0.76 EPS for 2024, Proposes NT$1.3 Dividend Per Share
2025-04-24
BiOptic Inc. (Stock Code: 6850) announced today (April 24) that its Board of Directors has approved the financial report and earnings distribution plan for fiscal year 2024. For the year 2024, BiOptic Inc. reported consolidated revenue of NT$202 million, representing an 11% year-on-year decrease. Net income attributable to the parent company was NT$22.73 million, down 40% year-on-year, with earnings per share (EPS) of NT$0.76. Despite the decline, the Board has proposed an above-average dividend payout of NT$1.3 per share, including NT$0.3 in cash dividends and NT$1 in stock dividends.
BiOptic Inc., Hermo Electric, and GGA Sign MOU to Expand Presence in Japan’s Market
2025-04-16
BiOptic Inc. (Stock Code: 6850) announced today (16th) that it has signed a Memorandum of Understanding (MOU) with Hermo Electric Co., Ltd. and GGA Corp. The three parties will combine their respective strengths to jointly expand into Japan’s biotechnology innovation and medical diagnostics markets, aiming to seize significant opportunities in the precision health sector.
